Pictet Asset Management (Switzerland)’s Recursion Pharmaceuticals RXRX Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$112K	Buy	+14,987	New	+$105K	﹤0.01%	1840

Other funds holding RXRX

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

DCI

Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s RXRX Position: Q2 2023 in Review

Pictet Asset Management (Switzerland) opened a new position in Recursion Pharmaceuticals (RXRX) in Q2 2023: 14,987 shares worth $112K. The stake represents ﹤0.01% of the portfolio and ranks #1840 among its holdings.

158 funds tracked by Wall St. Rank hold RXRX as of Q2 2023.

Pictet Asset Management (Switzerland) held 14,987 shares of Recursion Pharmaceuticals worth $112K as of Q2 2023.
Recursion Pharmaceuticals was a new Pictet Asset Management (Switzerland) position in Q2 2023.
Recursion Pharmaceuticals made up ﹤0.01% of Pictet Asset Management (Switzerland)'s portfolio in Q2 2023, its #1840 holding.
158 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2023.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 10 Aug 2023.